The agency approved Truxima for three lymphoma indications, whereas European regulators approved it last year for all the same indications as the reference product, Roche's Rituxan.
The advancement of biosimilars moves another step forward today with the launch of versions of a rheumatoid arthritis and Crohn’s disease drug to European markets. The products, which come from South Korean firm Celltrion and its partners Hospira and Mundipharma, will be in competition with the Johnson & Johnson and Merck & Co. drug Remicade. […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
By Kurt R. Karst – Earlier this week, Celltrion Healthcare Co., Ltd. and Celltrion, Inc. (collectively “Celltrion”) filed a Complaint for Declaratory Judgment in the U.S. District Court for the District of Massachusetts seeking a judgment with respect to certain patents allegedly convering Janssen Biotech, Inc.’s (“Janssen’s”) biological product REMICADE. The Complaint marks the beginning […]